^
Association details:
| Biomarker: | KIT D816G |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
An activating KIT mutation induces crizotinib resistance in ROS1 positive lung cancer
Excerpt:
Here we describe a novel mechanism of crizotinib resistance in a ROS1+ NSCLC patient. The KITD816G mutation identified in the genomic DNA of the crizotinib-resistant ROS1+ tumor sample and confirmed by sequencing of the mRNA by RT-PCR was deemed a somatic mutation that was acquired following drug treatment with crizotinib as it was not present in the pre-treatment sample.
DOI:
10.1016/j.jtho.2016.04.001
